Persistent sexual side effects of finasteride: could they be permanent?
Irwig, Michael S.
The Journal of Sexual Medicine · 9(11):2927-29322012
Abstract (paraphrased)
Prospective reassessment of 54 men (mean 14 months later): 96% still had persistent side effects and 89% met ASEX criteria for sexual dysfunction; duration of finasteride use did not predict recovery.
Plain-language summary (paraphrased)
Following up the same patients a year later, Irwig found the dysfunction hadn't resolved — 96% were still affected. How long someone had taken the drug didn't predict whether they'd recover, suggesting vulnerability is individual rather than dose-driven.
Why it’s in the corpus
Prospective evidence of non-resolution; supports individual susceptibility (genetic/epigenetic) over simple dose-response.
Some fields on this page come from the release’s Markdown edition, which carries text the JSON edition omits.
Related records
- Peer-reviewed paper
Persistent sexual side effects of finasteride for male pattern hair loss
Irwig, Michael S.; Kolukula, Swapna · The Journal of Sexual Medicine · 8(6):1747-1753
Interviews with 71 healthy men (21–46 y) who developed sexual side effects on finasteride: 94% low libido, 92% erectile dysfunction/decreased arousal, 69% orgasm problems; average 28 months of use, symptoms persisting on average 40 months after stopping.
PFS-0092011PFSCore corpus - Peer-reviewed paper
Post-finasteride syndrome: a surmountable challenge for clinicians
Traish, Abdulmaged M. · Fertility and Sterility · 113(1):21-50
Systematic evaluation of 250+ articles (1989–2019) on finasteride/dutasteride concludes PFS is a real constellation of persistent sexual, neurological, physical and mental effects in a susceptible subset, proposing endocrine disruption plus epigenetic…
PFS-0012020PFSCore corpus - Peer-reviewed paper
The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption
Traish, Abdulmaged M. · Current Sexual Health Reports · 10(3):88-103
Proposes that 5-alpha-reductase inhibitors act as endocrine disruptors, producing drug-induced epigenetic changes in gene expression that explain why symptoms persist after discontinuation.
PFS-0022018PFSCore corpus